GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuvectis Pharma Inc (NAS:NVCT) » Definitions » Retained Earnings

Nuvectis Pharma (Nuvectis Pharma) Retained Earnings : $-54.25 Mil (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Nuvectis Pharma Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Nuvectis Pharma's retained earnings for the quarter that ended in Dec. 2023 was $-54.25 Mil.

Nuvectis Pharma's quarterly retained earnings declined from Jun. 2023 ($-41.74 Mil) to Sep. 2023 ($-47.62 Mil) and declined from Sep. 2023 ($-47.62 Mil) to Dec. 2023 ($-54.25 Mil).

Nuvectis Pharma's annual retained earnings declined from Dec. 2021 ($-12.90 Mil) to Dec. 2022 ($-31.99 Mil) and declined from Dec. 2022 ($-31.99 Mil) to Dec. 2023 ($-54.25 Mil).


Nuvectis Pharma Retained Earnings Historical Data

The historical data trend for Nuvectis Pharma's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuvectis Pharma Retained Earnings Chart

Nuvectis Pharma Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Retained Earnings
-0.01 -12.90 -31.99 -54.25

Nuvectis Pharma Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -31.99 -36.03 -41.74 -47.62 -54.25

Nuvectis Pharma Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Nuvectis Pharma  (NAS:NVCT) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Nuvectis Pharma (Nuvectis Pharma) Business Description

Traded in Other Exchanges
N/A
Address
1 Bridge Plaza, 2nd Floor, Suite 275, Fort Lee, NJ, USA, 07024
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. Its pipeline products include NXP800, NXP900.
Executives
Ron Bentsur director, officer: Chairman & CEO 750 LEXINGTON AVE, 20TH FL, NEW YORK NY 10022
Marlio Charles Mosseri 10 percent owner 27 RIPPLEVALE GROVE, LONDON X0 N1 1HS
Enrique Poradosu officer: Chief Science and Business Off C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, FORT LEE NJ 07024
Shay Shemesh officer: Chief Development Officer C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, SUITE 275, FORT LEE NJ 07024
Michael J. Carson officer: Vice President, Finance C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, SUITE 275, FORT LEE NJ 07024
Kenneth Hoberman director 750 LEXINGTON AVENUE, 6TH FLOOR, NEW YORK NY 10024
Oliviero James F Iii director C/O KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022
Uri Ben-or officer: Int. Principal Financial Off. C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Matthew L. Kaplan director C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, SUITE 275, FORT LEE NJ 07024